New cancer drugs are revolutionary. Why don’t more patients get them?
A man diagnosed with Stage 3 colorectal cancer was not offered genetic testing, which could have revealed if specific drugs could target his cancer. This was the experience of John Ebers, though the article does not indicate if he received the drugs despite not being tested. The lack of genetic testing for certain patients is not explicitly explained.
AI-generated summary
Read this story on The Seattle Times